179 related articles for article (PubMed ID: 36614249)
1. RPS24 Is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma.
Li H; Gao L; Kang X; Wang X; Yu Y; Zhang Y; Chen H
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614249
[TBL] [Abstract][Full Text] [Related]
2. PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest.
Wang X; Yang J; Luo L; Li X; Zhang Y
Aging (Albany NY); 2023 May; 15(10):4122-4143. PubMed ID: 37211383
[TBL] [Abstract][Full Text] [Related]
3. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
4. SRSF7 is a promising prognostic biomarker in hepatocellular carcinoma and is associated with immune infiltration.
Shen W; Yuan L; Cheng F; Wu Z; Li X
Genes Genomics; 2024 Jan; 46(1):49-64. PubMed ID: 37985547
[TBL] [Abstract][Full Text] [Related]
5. Elevated
Cheng Q; Wang W; Liu J; Lv Z; Ji W; Yu J; Zhang W; Yang Y
Front Immunol; 2023; 14():1173848. PubMed ID: 37207207
[TBL] [Abstract][Full Text] [Related]
6. Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinoma.
Wu H; Liu S; Wu D; Zhou H; Sui G; Wu G
Cancer Med; 2023 Apr; 12(8):10138-10155. PubMed ID: 36855818
[TBL] [Abstract][Full Text] [Related]
7. METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.
Wang L; Peng JL
Sci Rep; 2023 Jul; 13(1):10755. PubMed ID: 37400463
[TBL] [Abstract][Full Text] [Related]
8. High MCM8 expression correlates with unfavorable prognosis and induces immune cell infiltration in hepatocellular carcinoma.
Yu M; Wang H; Xu H; Lv Y; Li Q
Aging (Albany NY); 2022 Dec; 14(24):10027-10049. PubMed ID: 36575045
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of Birc5 as a novel activated cell cycle program biomarker associated with infiltration of immunosuppressive myeloid-derived suppressor cells in hepatocellular carcinoma.
Liu Y; Chen X; Luo W; Zhao Y; Nashan B; Huang L; Yuan X
Cancer Med; 2023 Aug; 12(15):16370-16385. PubMed ID: 37326143
[TBL] [Abstract][Full Text] [Related]
10. LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Li L; Wang X; Ding Y; Hui N; Su B; Yang M
Eur J Med Res; 2022 Oct; 27(1):216. PubMed ID: 36307879
[TBL] [Abstract][Full Text] [Related]
11. Coupled scRNA-seq and Bulk-seq reveal the role of HMMR in hepatocellular carcinoma.
Su Z; He Y; You L; Zhang G; Chen J; Liu Z
Front Immunol; 2024; 15():1363834. PubMed ID: 38633247
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of SMS in the tumor microenvironment is associated with immunosuppression in hepatocellular carcinoma.
Xiang L; Piao L; Wang D; Qi LF
Front Immunol; 2022; 13():974241. PubMed ID: 36544774
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
14. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
15. BCL10 correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
Chen H; Li Z; Wu F; Ji W; Lu L; Wu Z; Huang Y; Wang W; Li S
IUBMB Life; 2023 Mar; 75(3):207-224. PubMed ID: 34928543
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma.
Ding L; Yu Q; Yang S; Yang WJ; Liu T; Xian JR; Tian TT; Li T; Chen W; Wang BL; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Front Immunol; 2022; 13():831101. PubMed ID: 35371079
[TBL] [Abstract][Full Text] [Related]
17. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
18. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
19. Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma.
Takahashi J; Masuda T; Kitagawa A; Tobo T; Nakano Y; Abe T; Ando Y; Kosai K; Kobayashi Y; Matsumoto Y; Yoshizumi T; Mori M; Mimori K
Oncology; 2022; 100(2):101-113. PubMed ID: 34724663
[TBL] [Abstract][Full Text] [Related]
20. Matrin-3 acts as a potential biomarker and promotes hepatocellular carcinoma progression by interacting with cell cycle-regulating genes.
He H; Jamal M; Zeng X; Lei Y; Xiao D; Wei Z; Zhang C; Zhang X; Pan S; Ding Q; Tan H; Xie S; Zhang Q
Cell Cycle; 2024 Jan; 23(1):15-35. PubMed ID: 38252499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
